Proteostasis Therapeutics seeks value creating product alliances. The company continues to pursue both in-licensing and out-licensing opportunities where our technology and expertise can be applied to provide unique insights and a competitive edge in development

• To date, we have established collaborations with Astellas Pharma and the Cystic Fibrosis Foundation Therapeutics (CFFT).

• The collaboration with Astellas Pharma (TYO:4503), which began in November 2014, is a worldwide collaboration to research and develop therapeutic candidates that modulate the Unfolded Protein Response (UPR). This collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. The Companies will conduct discovery, screening and preclinical research to identify lead compounds for clinical development.

• The collaboration with CFFT, which began in May 2012, is focused on the research, development, and commercialization of therapies to treat patients with a ΔF508 CFTR mutation by identifying small molecule modulators of protein homeostasis to correct the folding, trafficking, and function of ΔF508 CFTR.

• We received a grant from The Michael J. Fox Foundation in mid-2013 to fund preclinical research for disease-modifying therapies that treat Parkinson’s disease (PD) by enhancing the clearance of α-synuclein with potent and selective Usp14 inhibitors.

Our approach offers potential partners both the ability to explore novel biology as well as complement pre-existing research efforts. Therapeutic candidates identified with our platform modulate protein folding, trafficking, and clearance pathways and, therefore, create the potential of broader applicability for the treatment of human disease. The Proteostasis Therapeutics platform can directly generate candidates or support existing discovery programs using either phenotypic screens or screens involving specific molecular targets.

For information regarding partnering opportunities with Proteostasis Therapeutics, please contact Business Development at